Biotechnology company developing CRISPR-based genome editing technologies for therapeutic applications.
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing genome-edited allogeneic cell therapies aimed at treating hematologic malignancies and solid tumors both domestically and internationally. At the forefront of its portfolio are innovative product candidates like CB-010, an allogeneic CAR-T cell therapy targeting CD19, currently undergoing phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma. Additionally, CB-011, another leading candidate, focuses on anti-BCMA CAR-T cell therapy tailored for the treatment of relapsed or refractory multiple myeloma.
The company's robust pipeline also includes CB-012, designed as an allogeneic CAR-T cell therapy targeting CD371 for relapsed or refractory acute myeloid leukemia, and CB-020, an allogeneic CAR-NK cell therapy aimed at treating various solid tumors. Through strategic collaborations, such as its partnership with AbbVie Manufacturing Management Unlimited Company, Caribou Biosciences aims to accelerate the development and production of these innovative therapies, underscoring its commitment to addressing critical medical needs with cutting-edge genetic editing technologies.
Founded in 2011 and headquartered in Berkeley, California, Caribou Biosciences, Inc. has positioned itself at the forefront of the biopharmaceutical industry. With a focus on leveraging genome editing to enhance therapeutic outcomes, the company continues to drive forward its mission of pioneering transformative treatments for cancer and other challenging diseases.